Whole-exome sequencing reveals a comprehensive germline mutation landscape and identifies twelve novel predisposition genes in Chinese prostate cancer patients

• DOI: 10.1371/journal.pgen.1010373
• Publication Date: 2022-09-12T17:38:42Z
• Authors: Yonghao Liang; Peter Ka-Fung Chiu; Yao Zhu; Christine Yim-Pin...; Qing Xiong; Lin Wang; Jeremy Yuen-Chun ...; Qin Cao; Yu Wei; Ding-Wei Ye; Stephen Kwok-Wing...; Chi-Fai Ng
• Keywords: Male; 0301 basic medicine; China; Prostatic Neoplasms; QH426-470; 3. Good health; 03 medical and health sciences; Exome Sequencing; Genetics; Humans; Tyrosine; Genetic Predisposition to Disease; Protein Kinases; Germ-Line Mutation; Research Article

Prostate cancer is the most inheritable cancer with approximately 42% of disease risk attributed to inherited factors by studies of twins, indicating the importance of additional genetic screening to identify predisposition variants. However, only DNA damage repair (DDR) genes have been investigated thoroughly in prostate cancer. To determine the comprehensive germline mutation landscape in Chinese prostate cancer patients, we performed whole exome sequencing in 100 Han Chinese patients with prostate cancer in Hong Kong and identified deleterious germline mutations. A total of 36 deleterious germline variants in 25 genes were identified in 29% patients. Variants were found in eight pathways, including DNA methylation, DDR, and tyrosine-protein kinase. These findings were validated in an independent Chinese cohort of 167 patients with prostate cancer in Shanghai. Seven common deleterious-variant-containing genes were found in discovery cohort (7/25, 28%) and validation cohort (7/28, 25%) with three genes not described before (LDLR, MYH7 and SUGCT) and four genes previously reported (FANCI, ITGA6, PABPC1 and RAD54B). When comparing with that of a cohort of East Asian healthy individuals, 12 non-DDR novel potential predisposition genes (ADGRG1, CHD4, DNMT3A, ERBB3, GRHL1, HMBS, LDLR, MYH7, MYO6, NT5C2, NUP98 and SUGCT) were identified using the discovery and validation cohorts, which have not been previously reported in prostate cancer patients in all ethnic groups. Taken together, this study reveals a comprehensive germline mutation landscape in Chinese prostate cancer patients and discovers 12 novel non-DDR predisposition genes to lay the groundwork for the optimization of genetic screening.